Ibrahim Halil Sahin, Associate Professor of Medicine at the University of Michigan Medical School, shared a post on LinkedIn:
“I am not sure I am totally surprised with the COMMIT trial results, referring Atezo Mono arm in which PFS was noted to be only 4 months
This was 16 months for Pembrolizumab in KEYNOTE 177 and 39 months for Nivolumab monotherapy in CheckMate 8HW, which were also frontline trial for patients with MSI-H CRC
The reason I am not so surprised as we have seen this in ATOMIC trial in which Atezolizumab added modest benefit to the FOLFOX
These two trials beg the question whether Anti-PDL1 are right choices for MSI-H CRC…”
More posts featuring Ibrahim Halil Sahin.